Core Viewpoint - Panoro Minerals Ltd. has successfully closed the first tranche of its private placement, raising gross proceeds of C$2,918,200 through the sale of 7,295,500 units at a price of C$0.40 per unit, with plans to utilize the funds for various project developments and working capital [1][3]. Group 1: Offering Details - The first tranche of the offering consists of 7,295,500 units sold at C$0.40 each, totaling C$2,918,200 in gross proceeds [1]. - Each unit includes one common share and one common share purchase warrant, allowing the purchase of an additional common share at C$0.60 until November 21, 2028 [2]. - The offering is being managed by Red Cloud Securities Inc. as the lead agent and Cormark Securities Inc. as co-agent [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for infill drilling, metallurgical testing, pre-feasibility engineering, and an updated preliminary economic assessment for the Cotabambas Copper-Gold-Silver project [3]. - Additional funds will be directed towards working capital and general corporate purposes [3]. Group 3: Regulatory and Compliance - The units were issued under the listed issuer financing exemption, making the common shares and warrants immediately tradeable under Canadian securities legislation [4]. - The final tranche of the offering is expected to close around November 28, 2025, pending approval from the TSX Venture Exchange [6]. Group 4: Broker Compensation - The agents received a cash commission of 6.0% on the gross proceeds from the first tranche and non-transferable common share purchase warrants equivalent to 6.0% of the units sold [5].

Core Viewpoint - Plug Power Inc. is seeking stockholder approval for significant amendments to its charter, including increasing authorized common stock from 1.5 billion to 3.0 billion shares, to ensure flexibility for future capital needs and strategic initiatives [2][4]. Group 1: Special Meeting Details - The Special Meeting of Stockholders is scheduled for January 15, 2026, at 10:00 a.m. Eastern Time, and will be conducted virtually [1][10]. - The record date for stockholders to vote is December 4, 2025, emphasizing the importance of ensuring shares are available for voting [8]. Group 2: Proposed Amendments - The first proposal seeks to increase the authorized common stock to accommodate projected capital requirements and upcoming commitments, as current availability is less than 0.4% of authorized shares [2]. - The second proposal aims to amend the charter to align voting standards with recent Delaware statute changes, making it easier to amend the number of authorized shares in the future [3]. Group 3: Business Progress and Operational Momentum - Plug Power reported record hydrogen production in August 2025, with 324 metric tons produced and 97% uptime, showcasing the efficiency of its production technology [7]. - The company is advancing a multi-gigawatt electrolyzer development pipeline with over 8 GW of identified opportunities globally, indicating strong demand for clean hydrogen [7]. - Plug Power is expanding its material-handling fuel cell systems and has recently deployed next-generation systems for major logistics operators, reinforcing its market leadership [7]. - The company is enhancing its hydrogen storage and delivery capabilities to meet emerging industrial and data center demands, positioning itself as a comprehensive provider in the hydrogen economy [7].

SMITHFIELD, Va., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Smithfield Foods donated 32,000 pounds of protein to the 29th Annual Mayflower Marathon Holiday Food and Fund Drive to support the Virginia Peninsula Foodbank and Foodbank of Southeastern Virginia and the Eastern Shore. “Providing access to protein is a key part of our commitment to fighting hunger in the communities where we live and work,” said Jonathan Toms, senior community development manager for Smithfield Foods. “The Mayflower Marathon is a testament ...

-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability -- -- Tablet steady state showing Cmax/Cmin ratio <2 -- MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral ...

Core Points - Bank of America Corporation has crossed the legal threshold of 3% for direct voting rights and equivalent financial instruments in Umicore, reaching a total holding of 3.53% as of 18 November 2025 [2][8]. Company Overview - Umicore is a global advanced materials and recycling group, focusing on transforming precious and critical metals into functional technologies for everyday applications [6]. - The company operates with a unique circular business model that ensures continuous refinement and recycling of critical elements for reintegration into new applications [6]. Business Segments - Umicore has four main business groups: Catalysis, Recycling, Specialty Materials, and Battery Materials Solutions, which address resource scarcity and the demand for functional materials in clean technologies and mobility [7]. - The company emphasizes innovation and sustainability through tailored products and processes [7]. Financial Performance - In the first half of 2025, Umicore generated revenues of €1.8 billion (with a turnover of €8.7 billion), primarily focusing on clean mobility and recycling [10].

Transparency notification by Groupe Bruxelles Lambert S.A. In accordance with article 14, § 1 of the law of 2 May 2007 on the disclosure of major holdings, Umicore was recently notified by Groupe Bruxelles Lambert S.A. that it has crossed the legal threshold of 10% for the direct voting rights downwards on 18 November 2025. The total holding of direct voting rights and equivalent financial instruments of Groupe Bruxelles Lambert S.A. stands at 7.96% on 18 November 2025. Summary of the move by Groupe Bruxell ...

Core Insights - gategroup Holding AG successfully upsized and repriced its Term Loan B facilities, increasing its euro-denominated facility by EUR 215 million and its U.S. dollar-denominated facility by USD 75 million, enhancing liquidity and financial flexibility for long-term growth [1][2] Group 1: Financial Performance - The transaction experienced strong investor demand, leading to a margin reduction of 75 basis points to 350 basis points, which was better than initially expected [2] - gategroup maintains a well-balanced capital structure and strong liquidity position, allowing the company to execute its growth strategy and address upcoming debt maturities efficiently [3] Group 2: Company Overview - gategroup is a global leader in airline catering, retail-on-board, and hospitality products and services, operating over 200 units in more than 60 countries [4]

WILMINGTON, Del., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTC: ONFOP) (the "Company" or "Onfolio"), a company that combines digital assets, DeFi yield, and cash-flowing online businesses, today announced that it has received $4.75 million in investment proceeds under its previously announced financing agreement. The Company has allocated approximately $2.35 million toward business growth initiatives, repayment of debt and working capital, and approximately $2.4 million ...

Core Insights - Revive Therapeutics Ltd. is conducting a research study on Bucillamine as a potential treatment for nerve agent exposure in collaboration with Defence R&D Canada [1][2] - The study is ongoing, and final findings will be released with DRDC's authorization [2] - Revive is focused on developing therapeutics for infectious diseases and medical countermeasures, leveraging various FDA regulatory incentives [3] Company Overview - Revive Therapeutics specializes in the research and development of therapeutics for infectious diseases and medical countermeasures [3] - The company is exploring Bucillamine for nerve agent exposure and long COVID, alongside developing Psilocybin and molecular hydrogen therapeutics [3] Collaboration Details - The collaboration with DRDC provides expertise and infrastructure to support the development of medical countermeasures against nerve agent-induced brain injury [1]

Reims, November 21, 2025 On October 1, Vranken-Pommery Monopole decided to accept the offer from the Lanson-BCC Group, which was more attractive than that of the Vranken Company, for the sale of the Heidsieck & Co Monopole brand. In order to provide Vranken-Pommery Monopole with additional resources, strengthen its commercial development in the premium segment, and provide it with a cost-sharing arrangement, Compagnie Vranken has decided to license the Pompadour brand to it, with marketing set to begin in l ...